In 2023, a phase III clinical trial, CAPItello-291, showed that with the combination of capivasertib with fulvestrant in HER2- HR+ breast cancer, patients had a PFS of 7.2 months versus 3.6 months for the control group [65]. The gene discussed is ERBB2; the disease is breast carcinoma.